CPRX
Price
$25.89
Change
+$0.54 (+2.13%)
Updated
Jun 6, 04:13 PM (EDT)
Capitalization
3.09B
61 days until earnings call
LGND
Price
$106.02
Change
+$1.83 (+1.76%)
Updated
Jun 6, 02:25 PM (EDT)
Capitalization
2.01B
66 days until earnings call
Interact to see
Advertisement

CPRX vs LGND

Header iconCPRX vs LGND Comparison
Open Charts CPRX vs LGNDBanner chart's image
Catalyst Pharmaceuticals
Price$25.89
Change+$0.54 (+2.13%)
Volume$700
Capitalization3.09B
Ligand Pharmaceuticals
Price$106.02
Change+$1.83 (+1.76%)
Volume$100
Capitalization2.01B
CPRX vs LGND Comparison Chart
Loading...
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CPRX vs. LGND commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPRX is a Buy and LGND is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (CPRX: $25.36 vs. LGND: $104.08)
Brand notoriety: CPRX and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CPRX: 84% vs. LGND: 72%
Market capitalization -- CPRX: $3.09B vs. LGND: $2.01B
CPRX [@Biotechnology] is valued at $3.09B. LGND’s [@Biotechnology] market capitalization is $2.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPRX’s FA Score shows that 2 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • CPRX’s FA Score: 2 green, 3 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, CPRX is a better buy in the long-term than LGND.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPRX’s TA Score shows that 5 TA indicator(s) are bullish while LGND’s TA Score has 3 bullish TA indicator(s).

  • CPRX’s TA Score: 5 bullish, 2 bearish.
  • LGND’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CPRX is a better buy in the short-term than LGND.

Price Growth

CPRX (@Biotechnology) experienced а +3.17% price change this week, while LGND (@Biotechnology) price change was +3.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.54%. For the same industry, the average monthly price growth was +17.23%, and the average quarterly price growth was +3.31%.

Reported Earning Dates

CPRX is expected to report earnings on Aug 06, 2025.

LGND is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+11.54% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CPRX($3.09B) has a higher market cap than LGND($2.01B). LGND has higher P/E ratio than CPRX: LGND (46.19) vs CPRX (16.15). CPRX YTD gains are higher at: 21.514 vs. LGND (-2.865). CPRX has higher annual earnings (EBITDA): 269M vs. LGND (-122.1M). CPRX has more cash in the bank: 581M vs. LGND (209M). CPRX has less debt than LGND: CPRX (3.09M) vs LGND (4.45M). CPRX has higher revenues than LGND: CPRX (535M) vs LGND (181M).
CPRXLGNDCPRX / LGND
Capitalization3.09B2.01B154%
EBITDA269M-122.1M-220%
Gain YTD21.514-2.865-751%
P/E Ratio16.1546.1935%
Revenue535M181M296%
Total Cash581M209M278%
Total Debt3.09M4.45M69%
FUNDAMENTALS RATINGS
CPRX vs LGND: Fundamental Ratings
CPRX
LGND
OUTLOOK RATING
1..100
1615
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
1665
SMR RATING
1..100
3392
PRICE GROWTH RATING
1..100
4259
P/E GROWTH RATING
1..100
9291
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPRX's Valuation (61) in the Pharmaceuticals Other industry is in the same range as LGND (76) in the Biotechnology industry. This means that CPRX’s stock grew similarly to LGND’s over the last 12 months.

CPRX's Profit vs Risk Rating (16) in the Pharmaceuticals Other industry is somewhat better than the same rating for LGND (65) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than LGND’s over the last 12 months.

CPRX's SMR Rating (33) in the Pharmaceuticals Other industry is somewhat better than the same rating for LGND (92) in the Biotechnology industry. This means that CPRX’s stock grew somewhat faster than LGND’s over the last 12 months.

CPRX's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as LGND (59) in the Biotechnology industry. This means that CPRX’s stock grew similarly to LGND’s over the last 12 months.

LGND's P/E Growth Rating (91) in the Biotechnology industry is in the same range as CPRX (92) in the Pharmaceuticals Other industry. This means that LGND’s stock grew similarly to CPRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPRXLGND
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 16 days ago
69%
Bearish Trend 16 days ago
75%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
CPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NINDX60.39N/A
N/A
Columbia Large Cap Index Inst
ANEFX64.06N/A
N/A
American Funds New Economy A
GGOSX10.37N/A
N/A
Goldman Sachs Mid Cap Growth Svc
SHXPX13.79N/A
N/A
American Beacon Shapiro Equity Opps Inv
EKSRX5.99N/A
N/A
Allspring Diversified Income Bldr R6

CPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CPRX has been loosely correlated with VIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CPRX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPRX
1D Price
Change %
CPRX100%
+0.28%
VIR - CPRX
45%
Loosely correlated
-2.37%
CRNX - CPRX
44%
Loosely correlated
+0.59%
SANA - CPRX
44%
Loosely correlated
+9.70%
LGND - CPRX
42%
Loosely correlated
+0.27%
FOLD - CPRX
40%
Loosely correlated
-2.30%
More